Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 509 clinical trials
Identification of Fatty Liver With Advanced Fibrosis in Type 2 Diabetes Using Simple Fibrosis Scores and Electronic Reminder Messages

With this background, we aim to test the hypothesis that the use of simple fibrosis scores as part of a diabetes complications screening program followed by electronic reminder messages is more effective than usual care in prompting physicians to correctly identify patients with suspected NAFLD and advanced liver fibrosis for …

fibrosis
liver disease
nash
hepatic fibrosis
type 2 diabetes mellitus
  • 0 views
  • 16 Feb, 2024
  • 1 location
Combining Biomarkers (AFP AFP-L3 and PIVKA-II) and Image Tools for Early Detection of Hepatocellular Carcinoma

In this study, three biomarkers tests (AFP, AFP-L3 and PIVKA-II) and abdominal sonography or CT scans are performed every 6 months to detect hepatocellular carcinoma (HCC) early in patients with cirrhosis, a high-risk group of HCC. The aim of this study is to confirm the early HCC diagnosis rate in …

early detection
ascites
gastric varices
des-gamma-carboxy prothrombin
varicose veins
  • 0 views
  • 05 Aug, 2020
Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis

This study compares gadolinium contrast-enhanced Abbreviated MRI (AMRI) to standard ultrasound for Hepatocellular Carcinoma (HCC) screening and surveillance in subjects with liver cirrhosis.

carcinoma
hepatocellular carcinoma
cirrhosis
  • 0 views
  • 16 Feb, 2024
  • 1 location
The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics

This is a prospective, single-center, open-label, single-dose, Phase 1 study, to assess the effect of moderate hepatic impairment due to liver cirrhosis on the pharmacokinetics of aprocitentan (ACT-132577).

moderate hepatic impairment
serum pregnancy test
kidney function tests
moderate hepatic insufficiency
hepatic impairment
  • 0 views
  • 16 Feb, 2024
  • 1 location
Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis

This is an open-label, randomized study comparing a monitored ketogenic diet intervention using standard ketogenic diet (SKD) and standard of care (SOC) dietary recommendations for 16 weeks. Subjects enrolled in the standard of care group will receive a voucher to Weight Watchers after study completion.

fatty liver
ketogenic diet
cirrhosis
  • 0 views
  • 16 Feb, 2024
  • 1 location
Extension Study of Carvedilol RCT Study

Patients who have completed 2-years treatment in RCT Study of carvedilol will receive another 2-years extension therapy, aiming to investigate the long-term efficacy of carvedilol for the prevention of esophageal varices in treated HBV cirrhotic patients.

  • 0 views
  • 26 Aug, 2021
  • 13 locations
Comparison of Diuretic Effect With Furosemide Alone Versus the Combination of Furosemide and Albumin in Cirrhotic Patients

A common complication of the progression of cirrhosis is fluid retention (ascites, edema, or pleural effusion). Loop diuretics are the treatment of choice for fluid retention in cirrhotic patients; however, many of these patients demonstrate diuretic resistance, requiring higher doses of the diuretics to achieve adequate diuresis.

edema
ascites
loop diuretic
albumin human
fluid retention
  • 0 views
  • 16 Feb, 2024
  • 1 location
HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation

All international guidelines recommend 6-monthly ultrasound surveillance for patients at risk for liver cancer (hepatocellular carcinoma or HCC), such as patients with cirrhosis. The aim of surveillance is to detect HCC at an early stage when it is still potentially curable. Currently only 4 out of 10 HCCs are detected …

platelet count
carcinoma
contrast-enhanced magnetic resonance imaging
hypertension
ascites
  • 0 views
  • 16 Feb, 2024
  • 10 locations
A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

This is a randomized, single-blind, placebo-controlled, once daily (QD) dose study of CRV431 in presumed NASH F2/F3 subjects.

fibroscan
fatty liver
vcte
fibrosis
hepatic fibrosis
  • 0 views
  • 05 Aug, 2020
The Renal Deterioration Between Adjusted Dose TDF and Switching to TAF in CHB With Renal Impairment

Tenofovir is a nucleotide analog drug that works against both Human immunodeficiency virus (HIV) and HBV. TDF and TAF are prodrug of Tenofovir. TAF has a higher plasma stability than TDF, which makes TDF require a higher dose to get the concentration of drugs in the liver equal to the …

tenofovir
renal function
renal impairment
renal function test
hepatitis c
  • 0 views
  • 16 Feb, 2024
  • 1 location